Kornimate/medical-research-clean huggingface dataset:
early surgical effects and influencing factors of high tibial osteotomy in the treatment of knee osteoarthritis

Conditions: Osteoarthritis, Knee

Summary: exploring the factors influencing postoperative functional recovery after high tibial osteotomy

a retrospective study was conducted on patients who underwent hto at the first affiliated hospital of shandong first medical university from january 2018 to december 2020, and the preoperative and postoperative imaging indicators \[medial proximal tibial angle (mpta), joint line intersection angle (jlca), hip-knee-ankle angle (hka angle), knee weight-bearing line percentage (wbl%), postoperative distraction distance, postoperative distraction angle\] and knee joint function score \[including the american hospital for special surgery (hss) knee score, american knee society score (kss), lysholm score, western ontario and mcmaster universities osteoarthritis index score (womac), and all were included in logistic regression analysis to study the surgical effect and impact of hto factor

Eligibility criteria:
inclusion criteria: * medial knee oa, varus deformity is mainly in the tibia * aged ≤70 years old, with higher requirements for future activities * knee joint extension is limited to ≤10°, and flexion is \>90° * body mass index (bmi) ≤ 40 * no subchondral bone wear exclusion criteria: * there is a history of fracture or surgery of the lower limb on the operated side * traumatic koa * combined with nerve, muscle or connective tissue diseases * incomplete imaging data and loss of follow-up
short term outcome of primary precutaneous coronary intervention in ostial versus non ostial culprit proximal left anterior descending artery acute myocardial infraction

Conditions: Acute Myocardial Infarction

Summary: to compare short-term clinical outcomes of primary pci between the ostial lad-ami and the non-ostial lad-ami. the primary endpoint was the major cardiovascular events (mace) defined as being the composite of cardiac death, ami, stent thrombosis

current guidelines recommend percutaneous coronary intervention (pci) for most patients with st segment elevation acute myocardial infarction (stemi) or with non st segment elevation acute coronary syndrome (nsteacs) (1), (2). in stemi patients, pci is advised in all patients in the first 12 hours after onset of symptoms, the earlier the better (1). coronary revascularization does not always lead to coronary reperfusion. the development of devices and procedure has improved clinical outcomes of percutaneous coronary intervention (pci) to the culprit of acute myocardial infarction (ami) (3-5). however, proximal left anterior descending artery (lad)-ami has still been associated with high morbidity and mortality because of the broad ischemic area (6, 7). in fact, clinical outcomes were significantly worse in the proximal lad-ami as compared with the mid lad-ami.5) moreover, the proximal lad disease in stable angina was closely associated with early revascularization following optimal medical therapy (8). therefore, clinical guidelines regarding coronary revascularization have discriminated the proximal lad disease from other lad diseases (9). in terms of coronary revascularization, the ostial lad disease requires special attention in the proximal lad disease, because percutaneous coronary interventions (pci) can be more complex in the ostial lad disease than in the non-ostial proximal lad disease (10) even in the setting of ami, left-main-trunk (lmt)-to-lad crossover stenting was frequently required in the ostial lad disease (11).

Eligibility criteria:
inclusion criteria: 1. patients who were diagnosed as anterior stemi according to criteria developed by the european society of cardiology. 2. onset of maximal intensity of chest pain within 12 hours before procedure exclusion criteria: 1. patients presenting with previous pci to lad. 2. patients presenting with previous cabg. 3. patients presenting with nstemi acs.
prospective cohort study with central nervous system evaluation in diffuse large b-cell lymphoma

Conditions: Diffuse Large B-cell Lymphoma

Summary: this study is to evaluate the incidence of central nervous system (cns) relapse or metastasis in patients with diffuse large b-cell lymphoma.

we dichotomize patients according to the risk of cns involvement. then, we perform cns evaluation in patients at risk of cns involvement. we prospectively monitor whether cns relapse or metastasis occurs in patients with diffuse large b-cell lymphoma

Eligibility criteria:
inclusion criteria: 1. newly diagnosed patients with diffuse large b cell lymphoma 2. \> 20 years 3. life expectancy more than 6 months 4. written informed consent exclusion criteria: 1. refusal to informed consent 2. lymphomas other than diffuse large b cell lymphoma 3. primary cns lymphoma

Keywords: diffuse large b cell lymphoma central nervous system prognosis
cohort of patients with systemic granulomatosis and associated biological collection

Conditions: Granulomatosis

Summary: the grami-bio study is a prospective single-centre cohort study to recruit 150 patients followed up in the the bordeaux university hospital. the total duration of the grami-bio study is ten years (five years of inclusion with five years of follow-up): consecutive inclusion of patients meeting the definition of systemic granulomatosis. the main objective of this cohort is to describe to clinical progression of systemic granulomatosis and to collect blood fraction samples (serum bank, plasma bank, urine bank, dna bank) from subjects participating in the cohort.

systemic granulomatosis is a group of diseases whose common feature is the anatomopathological existence of giganto-cellular granulomas composed of macrophages, epithelial cells and cd4+ t lymphocytes. the exact cause of the development of these granulomas remains unknown, although numerous studies suggest the hypothesis of environmental factors (infectious, exposure to particles) and genetic susceptibility factors. the persistence of granulomas is deleterious, ultimately leading to local destruction and tissue damage resulting in fibrosis of neighbouring tissues. granulomatosis is a heterogeneous group in terms of aetiology: schematically, either an aetiology is identified: infection, environmental factors (berylliosis, pneumoconiosis), iatrogenesis (drugs), neoplasia, immune deficiency; or granulomatosis is said to be idiopathic, the most common case, falling within the definition of systemic sarcoidosis. therefore, with a view to future research work, it seems imperative to set up a biological bank of patients being monitored for systemic granulomatosis within the division. it is particularly important to identify genetic variants, circulating biomarkers associated with the onset, severity and response to treatment of these diseases. the main aim of the "grami-bio" study is to describe the clinical evolution of patients with systemic granulomatosis (sarcoidosis and other granulomatoses) followed at the bordeaux university hospital, and to collect samples from blood fractionation (serum bank, plasma bank, urine bank, dna, rna bank) to constitute a biobank.

Eligibility criteria:
inclusion criteria: * patients aged 18 or over * patients with systemic granulomatosis (diagnosis proven by anatomopathological sampling) at diagnosis. * persons affiliated to or benefiting from a social security scheme. * free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research). exclusion criteria: * patients infected with human immunodeficiency virus (hiv), hepatitis b virus (hbv) and/or hepatitis c virus (hcv) * pregnant or breast-feeding women * patients already receiving specific treatment for systemic granulomatosis * persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent.

Keywords: granulomatosis sarcoidosis biological collection
communication strategies to introduce psychology services

Conditions: Malignant Neoplasms of Independent (Primary) Multiple Sites

Summary: the goal of this research study is to learn about advanced cancer patients' preferences about how psychology services are introduced. this is an investigational study. up to 110 participants will be enrolled in this study. all will take part at md anderson.

if you agree to take part in this study, during an already-scheduled office visit, you will complete 3 questionnaires about your symptoms, your emotional health, and if you have ever participated in psychiatric or psychology services. these questionnaires should take about 9 minutes to complete. all participants will watch 2 short videos. the videos show actors playing a doctor, counselor, and patient, discussing psychology service options. each video is about 1 minute and 30 seconds long and will discuss the same material, but the content of each video will be different. the order in which they are presented will be randomly assigned (as in the flip of a coin). you will have an equal chance of seeing either video first. after you watch the second video, you will complete 3 questionnaires about whether you think 1 of the videos was better than the other, and about your attitude toward psychology services. these questionnaires should take about 4 minutes to complete. length of study: it should take about 16 minutes to watch both videos and to complete all questionnaires. your participation on this study will be over after you have completed the last questionnaire. other information: we will ask your caregiver(s) to leave the room while the videos are played. in case they decide to stay, we will ask them to keep silent.

Eligibility criteria:
inclusion criteria: 1. age \>/= 18 years-old 2. can speak, read, and understand english 3. diagnosis of locally advanced, recurrent, or metastatic disease 4. patients treated as outpatients by the supportive and palliative care team 5. normal cognitive status as determined by the interviewer based on the ability to understand the nature of the study and consent process exclusion criteria: 1. previous psychological counseling received in supportive care department 2. patients with severe symptom distress as assessed by nursing staff

Keywords: malignant neoplasms of independent (primary) multiple sites advanced cancer recurrent cancer metastatic disease palliative care videos questionnaires surveys
swallowing function before and after surgery for thyroid goiter

Conditions: Hypothyroidism

Summary: to date, there have been no comprehensive studies on swallowing function in patients undergoing surgery for multinodular goiter. we hypothesize that 1. multinodular goiter has significant effect on swallowing function in symptomatic and asymptomatic patients, which can be demonstrated by a standardized questionnaire and a formal swallowing evaluation and 2. surgery will improve swallowing function as measured post-operatively by these same parameters. patients with multinodular goiter will be asked to fill out a validated survey (swal-qol) on swallowing function in addition to undergoing a formal swallowing evaluation before and after surgery for multinodular goiter (subtotal thyroidectomy) and compared to patients undergoing total thyroidectomy for follicular cancer and less extensive thyroid surgery for other benign processes (lobectomy or lobectomy plus isthmusectomy).

detailed description not desired.

Eligibility criteria:
inclusion criteria: * thyroidectomy exclusion criteria: * na
staging prostate cancer with hybrid c11-choline pet/mr and mpmri

Conditions: Prostate Adenocarcinoma

Summary: the purpose of this study is to find out if a pet/mr scan in combination with standard mri and ct scans can improve the early detection and treatment of patients with prostate cancer.

high risk prostate cancer patients will undergo c11-choline pet/mr whole body fusion scan and pelvic mpmri for accurate staging. the pet/mr imaging findings, including the primary lesion with the prostate bed and pelvic lymph nodes, will be correlated with the histopathologic result. researchers aim to provide accurate one-stop shopping opportunity in diagnosis and staging of high risk prostate cancer using the c11-choline pet/mr scan.

Eligibility criteria:
inclusion criteria: 1. untreated patients with high-risk and very high-risk prostate cancer, who require clinical pelvic mpmri, ct, and bone scan as standard clinical care for diagnosis and management of prostate cancer. exclusion criteria: 1. patients who already received primary treatment or neo-adjuvant therapy. 2. patients who refuse undergoing routine clinical imaging (i.e., pelvic mpmri, ct, bone scan) for staging. reimbursement of pelvic mpmri in this study is denied. ct and bone scan may be done elsewhere outside of mayo clinic but should be of diagnostic quality. research c-11 choline pet/mr will not substitute pelvic mpmri, ct, or bone scan in this study. 3. patients cannot tolerate mri (e.g., claustrophobia, severe back pain or spasm, involuntary movement \[e.g., tremor, dystonia\]). 4. patients have total hip arthroplasty (tha), which can cause substantial susceptibility artifact and degrade image quality of mpmri. 5. patients have cardiac pacemaker, cochlear implants, neurostimulator, medical device which is unsafe at 3 tesla, or foreign metallic body in the eyes or orbit. 6. patients have contraindication to gadolinium based mr contrast agents (e.g., renal failure, severe reaction to gadolinium based mr contrast agents). epidermal growth factor receptor (egfr) should be above 30 within 30 days the time of mpmri.

Keywords: high risk prostate cancer c11-choline pet/mr mpmri
diagnostic and prognostic significance of computerized cytologic morphometry of the thyroid neoplasm

Conditions: Computerized Cytomorphometry

Summary: the prevalence of thyroid nodule is worldwide high. about 40% of normal population has thyroid nodules and about 5% are malignancy. it is important to differentiate malignancy from benign nodules because the management is completely different. nowadays, the gold standard is fine needle aspiration cytology (fnac) examination. the overall sensitivity and specificity is fair (\~90%), but still has its limitation that some results are indeterminate in about 15% of the nodules. these obstacles are especially troublesome for papillary and follicular thyroid cancer that leads to delayed diagnosis, incomplete resection, and repeated operation. preoperative evaluation of the prognosis is extraordinary important for cancer management. however, current prognostic scoring systems is only applicable after surgery. hence, we urgently need a better risk-stratification system for individual-tailored treatment, and genetic-based computerized morphometry study seems to be the most realistic and promising one. the goal of this study is to propose a reliable method for diagnosis and prognosis of papillary thyroid cancer and follicular thyroid cancer through analyzing cellular morphologic characteristics.


Eligibility criteria:
inclusion criteria: * patients who previously had received thyroid fine needle aspiration cytology examination exclusion criteria: * patients who are younger than 20 years old
clinical trial of concomitant hip arthroscopy during pao

Conditions: Hip Dysplasia

Summary: the study will assess the outcomes of patients treated with concomitant hip arthroscopy at the time of periacetabular osteotomy (pao) for patients with hip dysplasia compared with patients treated with pao alone.

there are currently no absolute indications for intraarticular assessment at the time of periacetabular osteotomy (pao). based on investigators' review of the literature and experience, patients who may benefit from intraarticular assessment are those with radiographic or mri evidence of damage where an intraarticular inspection may help in determining whether a pao is a reasonable procedure, those with mechanical symptoms likely related to labral pathology, round ligament or cartilage problems and those with hip dysplasia and cam deformities with limited range of motion that may benefit from femoral head neck junction osteochondroplasty. however, despite these relative indications today there is no clear evidence to suggest that these patients will do better than those that do not have intraarticular work done. hence, the objective of this project is to determine whether intraarticular work at the time of pao surgery leads to improved pain and function when compared to patients that do not undergo intraarticular work at the time of pao.

Eligibility criteria:
inclusion criteria: * diagnosis of hip dysplasia (ddh) electing periacetabular osteotomy (pao) for treatment * skeletally mature * age 15 - 55 * tonnis grade 0 or 1 osteoarthritis (minimal or no arthritis) * ability to receive a standard of care preoperative (magnetic resonance imaging) mri arthrogram of the hip exclusion criteria: * pregnant women * previous surgery about the hip * patients receiving pao for acetabular retroversion in the absence of ddh * previous hip arthroscopy to address intra-articular pathology
phase i, open label, single center safety study of [f-18]flt

Conditions: Brain Cancer

Summary: this is a ten subject, phase 1 study. the purpose of the phase 1 study is to demonstrate drug safety in a target group of subjects with high grade brain cancer. this population represents a potential clinical population that may benefit from this pet imaging tracer. the study will also begin collection of baseline imaging data and allow us to gain information to improve design and conduct of future trials.

this is a ten subject, phase 1 study. the purpose of the study is to demonstrate drug safety in a group with high grade brain tumors and to evaluate cell proliferation with f-18 flt. flt is known to clear out of normal brain and detect brain tumor. this population represents a potential clinical population that may benefit from this pet imaging tracer. this information will help improve the design and conduct of future f-18 flt clinical trials.

Eligibility criteria:
inclusion criteria: * subject may be male or female and of any race / ethnicity; * at the time of study drug dosing, the subject has reached his or her 18th birthday; * subject has histologic diagnosis of one of the following malignancies - glioblastoma gliosarcoma, anaplastic mixed/anaplastic oligodendroglioma or (anaplastic) astrocytoma with lesion visible on ct or mr and minimum histological grade of iii/iv; * subject with suspect radiation necrosis that are planned for re-section; * subject or subject's legally acceptable representative provides informed consent; * subject is capable of complying with study procedures and able to lie still in the pet scanner; * subject is capable of communicating with study personnel; * subject has adequate liver and kidney function exclusion criteria: * subject is pregnant or nursing; * subject is anemic (as defined as a hemoglobin level \<10); * subject has not received chemotherapy or radiation therapy within the two weeks prior to imaging. * subject has as reflected by a serum liver enzymes outside the normal laboratory reference range; * subject has a history of chronic liver disease, which may compromise liver function; * subject has kidney disease as reflected by a serum creatinine outside the normal laboratory reference range; * subject has prior history of stroke or other condition of the head or neck that, in the investigator's opinion, might affect circulation to the brain or image interpretation (examples include, but are not limited to, previous stroke with cystic softening and cerebral deformity, or arteriovenous malformation); * subject has a history of significant cerebrovascular disease; * subject has any other condition or personal circumstance that, in the judgment of the investigator, might interfere with the collection of complete good quality data * subject has previously received \[f-18\]flt at any time, or any other investigational product within the past two weeks.
subcutaneously administered campath in cd52 expressing hematologic malignancies

Conditions: Hematologic Malignancies

Summary: this phase i study will involve escalating doses of campath until the goal dose for the cohort is tolerated. the campath goal dose will be administered to the patient subcutaneously (sq) 3 times per week for up to 12 weeks.


Eligibility criteria:
inclusion criteria: * patients with relapsed or refractory hematologic malignancy. the anticipated patient population are patients with chronic lymphocytic leukemia (cll), non-hodgkin's lymphoma or myeloma * patients with a history of a hematologic malignancy that has previously been shown by flow cytometry or immunophenotyping analysis to express cd52 * any chemotherapy, major surgery or irradiation must have been completed at least four (4) weeks before enrollment in this study (6 weeks for mitomycin-c or nitrosourea) * patients have recovered from the acute side effects due to prior therapy * life expectancy of \> 3 months * world health organization (who) performance status 0-2 * 18 years of age or older * adequate organ function as defined in the protocol exclusion criteria: * prior therapy with campath * use of an investigational agent within two (2) weeks prior to study enrollment * history of anaphylaxis following exposure to humanized monoclonal antibodies * known human immunodeficiency virus (hiv) positive * prior autologous bone marrow or stem cell transplant if within six (6) months of study entry * a history or prior allogenic bone marrow transplant or organ transplant * known, symptomatic central nervous system (cns) involvement with lymphoma * pregnant or lactating women * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (excluding skin infection, lower urinary tract infection, or oral infection), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Keywords: cd52 expressing hematologic malignancies
investigation of the effect of e.-coli-nissle as supporting therapy to standard care of diabetes mellitus type ii

Conditions: Diabetes Mellitus Type II

Summary: this is a pilot study to investigate the effect of e.-coli-nissle as supporting therapy to antidiabetic standard care in patients with diabetes mellitus type ii


Eligibility criteria:
inclusion criteria: * diabetes mellitus type 2; * hba1c \>7 % (stable für 6 months, max. variation of 0,5%) * stable oral antidiabetic therapy for 6 months with metformin, vildagliptin, gliniden or without oral antidiabetics * age of 45 to \<80 years (men and women) exclusion criteria: * myocardial infarction or stroke within the last 5 years * therapy with acarbose * acute peripheral arterial disease within the last 12 months * instable metabolic situation * uncontrolled hypertension * body-mass-index ≥ 35 kg/m² * smokers * daily consumption of probiotic food * malignant disease within the last 5 years * status post transplantation * immunosuppressive therapy within the last 3 months * therapy with antibiotics * macroalbuminuria * severe liver disease

Keywords: diabetes